Dry Eye Treatment Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology (Broadband Light (BBL), Intense Pulsed Light (IPL), Meibomian Gland Expression (MGX), Combination (MGX+IPL)), By End Use (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region and Competition, 2020-2030F

Market Overview

The Global Dry Eye Treatment Devices Market will grow from USD 292.49 Million in 2024 to USD 489.19 Million by 2030 at a 8.95% CAGR. The global dry eye treatment devices market encompasses medical technologies developed to alleviate symptoms and address the underlying causes of dry eye disease, a multifactorial condition affecting the ocular surface. Key drivers supporting market growth include the rising global prevalence of dry eye syndrome, an expanding aging population, and increased digital screen exposure. Furthermore, continuous technological advancements offering more effective and non-invasive diagnostic and therapeutic solutions significantly contribute to market expansion.

This expanding need for intervention is underscored by clinical observations; according to research presented at the American Academy of Ophthalmology 2025 Annual Meeting, nearly 40% of pediatric patients at a California clinic met dry eye diagnostic criteria, reflecting a 42% increase since before the pandemic. Despite this clear demand, a significant challenge for market expansion is the high cost associated with these advanced dry eye treatments and devices, potentially limiting widespread patient accessibility.

Key Market Drivers

The global dry eye treatment devices market is significantly driven by the increasing prevalence of dry eye disease worldwide. This rise is not only a result of enhanced diagnostic capabilities but also a direct consequence of modern lifestyle factors, including prolonged digital screen time and environmental influences. A considerable portion of the global population now experiences dry eye symptoms, which fuels a consistent demand for effective treatment solutions. According to Acta Scientific Ophthalmology, in April 2024, a study conducted in India revealed a prevalence rate of 67% for dry eye disease among participants, illustrating the substantial impact of the condition in large populations. This widespread occurrence necessitates ongoing medical intervention and expands the patient pool requiring various therapeutic devices.

Advancements in dry eye treatment device technology serve as a pivotal market accelerant. Innovations are consistently introducing more targeted, less invasive, and highly efficacious devices that improve patient compliance and clinical outcomes. These technological strides encompass sophisticated diagnostic tools that offer precise disease staging and novel therapeutic devices. A notable development was reported by Modern Optometry, in February 2025, concerning Lacrifill Canalicular Gel by Nordic Pharma, which launched in May 2024 as a biocompatible, crosslinked hyaluronic acid gel designed to occlude the canalicular system and prolong the eye's natural tears on the ocular surface. This continuous evolution ensures clinicians have a broader array of treatment options. This segment of the market remains dynamic; according to BioSpace, in November 2025, Sight Sciences reported its Dry Eye revenue for the third quarter of 2025 as $0.2 million.

Download Free Sample Report

Key Market Challenges

A significant challenging factor in the global dry eye treatment devices market is the high cost associated with advanced treatments and devices. This financial burden directly impedes widespread patient accessibility, particularly for individuals without comprehensive insurance coverage or in regions with constrained healthcare budgets. When the cost of therapeutic options becomes prohibitive, a substantial segment of the patient population cannot access necessary interventions, regardless of their clinical effectiveness. This creates a barrier to treatment adoption, directly limiting the potential market reach for innovative devices.

The affordability issue substantially constrains market penetration and overall growth. For instance, according to the Contact Lens Association of Ophthalmologists, in 2024, the median annual out-of-pocket treatment cost for dry eye was $500, with reported expenses ranging from $200 to $1,320. Such costs can be a significant deterrent for many patients, leading to delayed or forgone treatments. This directly impacts the revenue streams of device manufacturers and slows the market's expansion despite the rising prevalence of dry eye disease.

Key Market Trends

The global dry eye treatment devices market is currently shaped by the increasing adoption of at-home and wearable solutions, alongside the integration of artificial intelligence for personalized care. These trends reflect a market evolution towards greater patient convenience and more precise therapeutic interventions.

The market for dry eye treatment devices is experiencing a notable shift towards consumer-centric solutions with the increasing proliferation of at-home and wearable treatment devices. This trend is driven by patient demand for convenience, reduced clinic visits, and continuous management of dry eye symptoms in their daily lives. These devices offer patients greater autonomy over their treatment regimens, potentially improving compliance and long-term outcomes. Manufacturers are responding by developing innovative portable and user-friendly options, as evidenced when Reichert announced plans to introduce four new dry eye assessment and treatment devices to the U.S. market, including the Activa eye mask for meibomian gland dysfunction, through a partnership with SBM Sistemi, according to Review of Optometry in December 2023. This expansion into accessible, direct-to-consumer devices broadens the market reach beyond traditional clinical settings.

The integration of artificial intelligence for personalized treatment represents a significant technological advancement in the dry eye treatment devices market. AI algorithms enable sophisticated analysis of patient-specific data, including medical history, diagnostic results, and lifestyle factors, to formulate highly customized and effective treatment protocols. This personalization enhances diagnostic accuracy, streamlines clinical workflows, and holds the potential for improved patient outcomes by tailoring interventions to individual disease profiles. For example, CSI Dry Eye Software rolled out a new version of its artificial intelligence-based platform in June 2025, which is designed to analyze patient data from various tests and questionnaires to identify root causes and develop tailored treatment plans for dry eye disease. Such advancements allow for more precise disease management and adaptive treatment strategies.

Segmental Insights

The Meibomian Gland Expression (MGX) segment is rapidly emerging as a leading contributor to the global dry eye treatment devices market. This accelerated growth is primarily driven by its effectiveness in addressing Meibomian Gland Dysfunction (MGD), which is recognized as a prevalent underlying cause of dry eye disease. MGX technology directly targets and clears blocked meibomian glands, thereby restoring their crucial function of producing the essential oil layer of the tear film. This precise intervention significantly improves tear film stability, reduces excessive tear evaporation, and provides lasting relief from dry eye symptoms, moving beyond temporary symptomatic treatments. The procedure is also favored for its non-invasive nature and demonstrated efficacy in improving patient comfort and overall ocular health.

Regional Insights

North America leads the global dry eye treatment devices market, primarily driven by a significant prevalence of dry eye disease across its population. The region benefits from a highly advanced and robust healthcare infrastructure, facilitating the early adoption of innovative diagnostic and therapeutic devices. A strong regulatory framework, notably enforced by institutions like the U.S. Food and Drug Administration, supports the development and market entry of novel treatment technologies. Furthermore, substantial investments in research and development, coupled with high awareness regarding dry eye conditions and favorable reimbursement policies, contribute to North America's dominance in this specialized medical device sector.

Recent Developments

• In June 2024, Nordic Pharma, Inc. launched LACRIFILL Canalicular Gel, a novel dry eye therapy device. This 501(k)-cleared device, derived from cross-linked hyaluronic acid, is designed to temporarily block tear drainage. Administered as an in-office procedure, it occludes the canalicular system, allowing the eye's natural tears to remain on the ocular surface for an extended period. The device provides a customizable treatment option, indicated for use up to six months, for patients seeking relief from dry eye symptoms by enhancing natural tear retention.

• In 2024, Reichert announced the impending launch of four new dry eye treatment devices in the U.S. market, resulting from its partnership with Italian manufacturer SBM Sistemi. These devices included IDRA and OS1000, designed for comprehensive ocular surface evaluation. The DSLC200, an anterior imaging camera system, was enhanced with a dry eye module (DEM100) to transform slit lamps into advanced assessment platforms. Additionally, the Activa device, an eye mask, was introduced to treat meibomian gland dysfunction and evaporative dry eye by heating and stimulating the glands through micro-vibrations, expanding diagnostic and therapeutic options.

• In 2025, Novoxel's Tixel i, a thermomechanical device for meibomian gland dysfunction (MGD), garnered attention for its novel approach. This device utilizes a 400˚C heated, pulsating titanium tip to noninvasively restore meibomian gland function, liquify meibum, and enhance tear stability. Clinical studies have indicated that the Tixel i can provide significant relief from symptoms in a short treatment time, demonstrating improvements in gland function and a notable reduction in Ocular Surface Disease Index scores for individuals suffering from evaporative dry eye disease.

• In 2025, Lumenis continued to advance dry eye treatment with its OptiLIGHT Intense Pulsed Light (IPL) therapy and Dynamic Muscle Stimulation therapy (DMSt). OptiLIGHT IPL remains a significant device for managing meibomian gland dysfunction (MGD)-related dry eye disease by reducing inflammation and improving gland function through targeted light pulses. Complementing this, Lumenis's DMSt was offered to patients with weak orbicularis function or incomplete blinking, strengthening facial muscles to restore proper blink mechanics and eyelid tone, thereby supporting the eye's natural protection against evaporation.

Key Market Players

• MiBo Medical Group
• Sight Sciences, Inc.
• Lumenis Be Ltd.
• ESW Vision SAS
• Johnson & Johnson Vision Care, Inc.
• Alcon, Inc.
• Koninklijke Philips N.V.
• Leriva SA

Report Scope:

In this report, the Global Dry Eye Treatment Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Dry Eye Treatment Devices Market, By Technology:

o   Broadband Light (BBL)

o   Intense Pulsed Light (IPL)

o   Meibomian Gland Expression (MGX)

o   Combination (MGX+IPL)

• Dry Eye Treatment Devices Market, By End Use:

o   Hospitals & Clinics

o   Ambulatory Care Centers

o   Others

• Dry Eye Treatment Devices Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Dry Eye Treatment Devices Market.

Available Customizations:

Global Dry Eye Treatment Devices Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Dry Eye Treatment Devices Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]